in

Sun Pharma gets CDSCO panel nod to study COPD drug combination

New Delhi: Pharmaceutical major, Sun Pharma has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the active Post-marketing Surveillance (PMS) Study of the fixed-dose combination drug Fluticasone Furoate 200mcg plus Vilanterol 25mcg powder for inhalation.

However, this approval is subject to conditions that the follow-up of the study should be up to 06 months.

Furthermore, the expert panel suggested, “The details of the last visit including the test parameters should be mentioned at 06 months and telephonic follow-up should be done in the 4th and 5th months to assess the symptom analysis so as to rule out any worsening or exacerbation.”

This came after the drug major Sun Pharma presented the active post-marketing surveillance (PMS) study protocol before the committee as per the condition mentioned in Form CT-23 dated 31.10.2022.

The fixed-dose combination drug Fluticasone Furoate 200mcg plus Vilanterol 25mcg powder for inhalation is used in the treatment of Chronic obstructive pulmonary disease (COPD) and Asthma.

Fluticasone furoate works by blocking the production of certain chemicals in the body which causes inflammation (redness and swelling) and allergies. Vilanterol works by relaxing air passages in the lungs, making breathing easier.

At the recent SEC meeting for Pulmonary held on the 21st of March 2023, the expert panel reviewed the active PMS study protocol of the FDC drug Fluticasone Furoate 200mcg plus Vilanterol 25mcg powder for inhalation.

After detailed deliberation, the committee recommended for conducting the active PMS study with the following conditions:

1. The follow-up of the study should be up to 06 months.

2. The details of the last visit including the test parameters should be mentioned at 06 months accordingly.

3. Telephonic follow-up should be done in the 4th and 5th months to assess the symptom analysis so as to rule out any worsening or exacerbation.

In addition, the expert panel suggested that the result of the study should be presented before the committee for review.

Also Read:Revise CT protocol: CDSCO Panel tells Intas on antipsychotic Drug Endoxifen

What do you think?

Written by

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

ChatGPT Maker OpenAI Plans Measures to Address Concerns in Italy Ban

Liver drug may prevent and lower severity of COVID 19 infection